Acuite upgrades credit ratings of Bal Pharma

22 Feb 2022 Evaluate

Credit rating agency -- Acuite has upgraded credit ratings of Bal Pharma. Long Term Fund based facilities has been upgraded to ‘BBB-’ stable from ‘BB+’ positive. Short term Non fund based facilities has been upgraded to ‘A3’ from ‘A4+’. Also, Long term-Term Loan has been upgraded to ‘BBB-’ stable from ‘BB+’ positive.

Bal Pharma, incorporated in 1987 is engaged in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.

Bal Pharma Share Price

125.00 0.05 (0.04%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.